Oral Progesterone for Prevention of Preterm Birth
| Status: | Completed |
|---|---|
| Conditions: | Women's Studies |
| Therapuetic Areas: | Reproductive |
| Healthy: | No |
| Age Range: | 18 - 45 |
| Updated: | 2/20/2019 |
| Start Date: | November 2006 |
| End Date: | January 2009 |
Prevention of Recurrent Preterm Birth With Micronized Progesterone
To evaluate whether daily oral micronized progesterone is effective in preventing recurrent
spontaneous preterm birth (RSPB) and whether micronized progesterone use increases maternal
serum progesterone levels.
spontaneous preterm birth (RSPB) and whether micronized progesterone use increases maternal
serum progesterone levels.
To evaluate whether 400 mg daily oral micronized progesterone from 16 to 34 weeks' is
effective in preventing recurrent spontaneous preterm birth (RSPB) and whether micronized
progesterone use increases maternal serum progesterone levels.
effective in preventing recurrent spontaneous preterm birth (RSPB) and whether micronized
progesterone use increases maternal serum progesterone levels.
Inclusion Criteria:
- pregnant women less than 20 weeks' gestation who had at least one prior spontaneous
preterm birth of a liveborn baby between 20 & 0/7 weeks' and 36 & 6/7 weeks'
gestation.
Exclusion Criteria:
- multiple gestations, the presence of major fetal anomalies, progesterone use in the
current pregnancy (ongoing or past), the presence of a cervical cerclage, and the
presence of a placenta previa.
We found this trial at
1
site
Miami Valley Hospital Miami Valley Hospital (MVH) is passionate about providing the most recent medical...
Click here to add this to my saved trials
